Current long-acting muscarinic antagonists for the treatment of asthma

References

• GINA Report, Global strategy for asthma management and prevention; 2019 [cited 2021 Feb 20]. Available from: https://ginasthma.org/wp-content/uploads/2019/06/GINA-2019-main-report-June-2019-wms.pdf
   Google Scholar
• To T, Stanojevic S, Moores G, et al. Global asthma prevalence in adults: findings from the cross-sectional world health survey. BMC Public Health. 2012;12(1):204.
   PubMed Web of Science ®Google Scholar
• Lai CKW, Beasley R, Crane J, et al. Global variation in the prevalence and severity of asthma symptoms: phase three of the international study of asthma and allergies in childhood (ISAAC). Thorax. 2009;64(6):476–483.
   PubMed Web of Science ®Google Scholar
• Martinez FD, Vercelli D. Asthma. Lancet. 2013;382(9901):1360–1372.
   PubMed Web of Science ®Google Scholar
• Wenzel SE. Asthma phenotypes: the evolution from clinical to molecular approaches. Nat Med. 2012;18(5):716–725.
   PubMed Web of Science ®Google Scholar
• Papi A, Brightling C, Pedersen SE, et al., Asthma. Lancet. 391(10122): 783–800. 2018.
   PubMed Web of Science ®Google Scholar
• Rogliani P, Calzetta L, Matera MG, et al. Severe asthma and biological therapy: when, which, and for whom. Pulm Ther. 2020;6(1):47–66.
   PubMedGoogle Scholar
• Canonica GW, Baena-Cagnani CE, Blaiss MS, et al. Unmet needs in asthma: global asthma physician and patient (GAPP) survey: global adult findings. Allergy. 2007;62(6):668–674.
   PubMed Web of Science ®Google Scholar
• Reddel HK, Bateman ED, Becker A, et al. A summary of the new GINA strategy: a roadmap to asthma control. Eur Respir J. 2015;46(3):622–639.
   PubMed Web of Science ®Google Scholar
• Cazzola M, Ora J, Rogliani P, et al. Role of muscarinic antagonists in asthma therapy. Expert Rev Respir Med. 2017;11(3):239–253.
   PubMed Web of Science ®Google Scholar
• Cazzola M, Puxeddu E, Matera MG, et al. A potential role of triple therapy for asthma patients. Expert Rev Respir Med. 2019;13(11):1079–1085.
   PubMed Web of Science ®Google Scholar
• Radovanovic D, Santus P, Blasi F, et al. The evidence on tiotropium bromide in asthma: from the rationale to the bedside. Multidiscip Respir Med. 2017;12(1):12.
   PubMedGoogle Scholar
• Molfino NA, Slutsky AS, Julià-Serdà G, et al. Assessment of airway tone in asthma: comparison between double lung transplant patients and healthy subjects. Am Rev Respir Dis. 1993;148(5):1238–1243.
   PubMedGoogle Scholar
• Bossé Y, Chin LYM, Paré PD, et al. Chronic activation in shortened airway smooth muscle: a synergistic combination underlying airway hyperresponsiveness? Am J Respir Cell Mol Biol. 2010;42(3):341–348.
   PubMed Web of Science ®Google Scholar
• Meurs H, Oenema TA, Kistemaker LEM, et al. A new perspective on muscarinic receptor antagonism in obstructive airways diseases. Curr Opin Pharmacol. 2013;13(3):316–323.
   PubMed Web of Science ®Google Scholar
• Verbout NG, Lorton JK, Jacoby DB, et al. Atropine pretreatment enhances airway hyperreactivity in antigen-challenged guinea pigs through an eosinophil-dependent mechanism. Am J Physiol Lung Cell Mol Physiol. 2007;292(5):L1126–1135.
   PubMed Web of Science ®Google Scholar
• Barnes PJ. Severe asthma: advances in current management and future therapy. J Allergy Clin Immunol. 2012;129(1):48–59.
   PubMed Web of Science ®Google Scholar
• Matera MG, Cazzola M. Muscarinic receptor antagonists. Handb Exp Pharmacol. 2017;237:41–62.
   PubMedGoogle Scholar
• Rogers DF. Motor control of airway goblet cells and glands. Respir Physiol. 2001;125(1–2):129–144.
   PubMedGoogle Scholar
• Arai N, Kondo M, Izumo T, et al. Inhibition of neutrophil elastase-induced goblet cell metaplasia by tiotropium in mice. Eur Respir J. 2010;35(5):1164–1171.
   PubMed Web of Science ®Google Scholar
• Calzetta L, Matera MG, Cazzola M. Pharmacological mechanisms leading to synergy in fixed-dose dual bronchodilator therapy. Curr Opin Pharmacol. 2018;40:95–103.
   PubMed Web of Science ®Google Scholar
• Cazzola M, Calzetta L, Rogliani P, et al. Interaction between corticosteroids and muscarinic antagonists in human airways. Pulm Pharmacol Ther. 2016;36:1–9.
   PubMed Web of Science ®Google Scholar
• Nabishah BM, Morat PB, Khalid BA, et al. Effect of acetylcholine and morphine on bronchial smooth muscle contraction and its modulation by steroid hormones. Clin Exp Pharmacol Physiol. 1990;17(12):841–847.
   PubMed Web of Science ®Google Scholar
• Jacoby DB, Yost BL, Kumaravel B, et al. Glucocorticoid treatment increases inhibitory M2 muscarinic receptor expression and function in the airways. Am J Respir Cell Mol Biol. 2001;24(4):485–491.
   PubMed Web of Science ®Google Scholar
• Walker FB, Kaiser DL, Kowal MB, et al., Prolonged effect of inhaled glycopyrrolate in asthma. Chest. 91(1): 49–51. 1987.
   PubMed Web of Science ®Google Scholar
• Moher D, Shamseer L, Clarke M, et al. Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015 statement. Syst Rev. 2015;4(1):1.
   PubMed Web of Science ®Google Scholar
• Schardt C, Adams MB, Owens T, et al. Utilization of the PICO framework to improve searching PubMed for clinical questions. BMC Med Inform Decis Mak. 2007;7(1):16.
   PubMed Web of Science ®Google Scholar
• Sterne JAC, Savović J, Page MJ, et al. RoB 2: a revised tool for assessing risk of bias in randomised trials. BMJ. 2019;366:l4898.
   PubMed Web of Science ®Google Scholar
• McGuinness LA. robvis: an R package and web application for visualising risk-of-bias assessments; 2019. [cited 2021 Feb 20]. Available from: https://github.com/mcguinlu/robvis.
   Google Scholar
• Guyatt G, Oxman AD, Akl EA, et al. GRADE guidelines: 1. Introduction-GRADE evidence profiles and summary of findings tables. J Clin Epidemiol. 2011;64(4):383–394.
   PubMed Web of Science ®Google Scholar
• Rogliani P, Ritondo BL, Calzetta L. Triple therapy in uncontrolled asthma: a network meta-analysis of Phase III studies. Eur Respir J. 2021;2004233. DOI:https://doi.org/10.1183/13993003.04233-2020.
   Google Scholar
• Kew KM, Dahri K. Long-acting muscarinic antagonists (LAMA) added to combination long-acting beta2-agonists and inhaled corticosteroids (LABA/ICS) versus LABA/ICS for adults with asthma. Cochrane Database Syst Rev. 2016;(1):CD011721
   Google Scholar
• Sobieraj DM, Baker WL, Nguyen E, et al. Association of inhaled corticosteroids and long-acting muscarinic antagonists with asthma control in patients with uncontrolled, persistent asthma: a systematic review and meta-analysis. JAMA. 2018;319(14):1473–1484. Erratum in: JAMA. 2018 May 8;319(18):1939
   Google Scholar
• Sobieraj DM, Baker WL, Nguyen E, Weeda ER, Coleman CI, White CM, Lazarus SC, Blake KV, Lang JE. Association of Inhaled Corticosteroids and Long-Acting Muscarinic Antagonists With Asthma Control in Patients With Uncontrolled, Persistent Asthma: A Systematic Review and Meta-analysis. JAMA. 2018 Apr 10;319(14):1473–1484. Erratum in: JAMA. 2018 May 8;319(18):1939
   Google Scholar
• Disse B, Reichl R, Speck G, et al. Ba 679 BR, a novel long-acting anticholinergic bronchodilator. Life Sci. 1993;52(5–6):537–544.
   PubMed Web of Science ®Google Scholar
• Lazarus SC, Krishnan JA, King TS, et al., Mometasone or tiotropium in mild asthma with a low sputum eosinophil level. N Engl J Med. 380(21): 2009–2019. 2019.
   PubMed Web of Science ®Google Scholar
• Kerwin E, Wachtel A, Sher L, et al. Efficacy, safety, and dose response of glycopyrronium administered by metered dose inhaler using co-suspension delivery technology in subjects with intermittent or mild-to-moderate persistent asthma: a randomized controlled trial. Respir Med. 2018;139:39–47.
   PubMed Web of Science ®Google Scholar
• Blais CM, Davis BE, Cockcroft DW. The effect of glycopyrronium and indacaterol, as monotherapy and in combination, on the methacholine dose-response curve of mild asthmatics: a randomized three-way crossover study. Respir Res. 2017;18(1):146.
   PubMed Web of Science ®Google Scholar
• Lee LA, Briggs A, Edwards LD, et al. A randomized, three-period crossover study of umeclidinium as monotherapy in adult patients with asthma. Respir Med. 2015;109(1):63–73.
   PubMed Web of Science ®Google Scholar
• Rajanandh MG, Nageswari AD, Ilango K. Pulmonary function assessment in mild to moderate persistent asthma patients receiving montelukast, doxofylline, and tiotropium with budesonide: a randomized controlled study. Clin Ther. 2014;36(4):526–533.
   PubMed Web of Science ®Google Scholar
• Rajanandh MG, Nageswari AD, Ilango K. Assessment of montelukast, doxofylline, and tiotropium with budesonide for the treatment of asthma: which is the best among the second-line treatment? A randomized trial. Clin Ther. 2015;37(2):418–426.
   PubMed Web of Science ®Google Scholar
• Peters SP, Kunselman SJ, Icitovic N, et al. Tiotropium bromide step-up therapy for adults with uncontrolled asthma. N Engl J Med. 2010;363(18):1715–1726.
   PubMed Web of Science ®Google Scholar
• Kerstjens HAM, Casale TB, Bleecker ER, et al. Tiotropium or salmeterol as add-on therapy to inhaled corticosteroids for patients with moderate symptomatic asthma: two replicate, double-blind, placebo-controlled, parallel-group, active-comparator, randomised trials. Lancet Respir Med. 2015;3(5):367–376.
   PubMed Web of Science ®Google Scholar
• Santanello NC, Zhang J, Seidenberg B, et al. What are minimal important changes for asthma measures in a clinical trial? Eur Respir J. 1999;14(1):23–27.
   PubMed Web of Science ®Google Scholar
• Bime C, Wei CY, Holbrook JT, et al. Asthma symptom utility index: reliability, validity, responsiveness, and the minimal important difference in adult asthmatic patients. J Allergy Clin Immunol. 2012;130(5):1078–1084.
   PubMed Web of Science ®Google Scholar
• Paggiaro P, Halpin DMG, Buhl R, et al. The effect of tiotropium in symptomatic asthma despite low- to medium-dose inhaled corticosteroids: a randomized controlled trial. J Allergy Clin Immunol Pract. 2016;4(1):104–113.e2.
   PubMed Web of Science ®Google Scholar
• Lee LA, Yang S, Kerwin E, et al. The effect of fluticasone furoate/umeclidinium in adult patients with asthma: a randomized, dose-ranging study. Respir Med. 2015;109(1):54–62.
   PubMed Web of Science ®Google Scholar
• Yang S, Goyal N, Beerahee M, et al. Dose-response modelling of umeclidinium and fluticasone furoate/umeclidinium in asthma. Eur J Clin Pharmacol. 2015;71(9):1051–1058.
   PubMed Web of Science ®Google Scholar
• Church A, Beerahee M, Brooks J, et al. Dose response of umeclidinium administered once or twice daily in patients with COPD: a randomised cross-over study. BMC Pulm Med. 2014;14(1):2.
   PubMedGoogle Scholar
• Kerwin E, Pascoe S, Bailes Z, et al. A phase IIb, randomised, parallel-group study: the efficacy, safety and tolerability of once-daily umeclidinium in patients with asthma receiving inhaled corticosteroids. Respir Res. 2020;21(1):148.
   PubMed Web of Science ®Google Scholar
• Barnes PJ. How corticosteroids control inflammation: quintiles prize lecture 2005. Br J Pharmacol. 2006;148(3):245–254.
   PubMed Web of Science ®Google Scholar
• Ora J, Calzetta L, Matera MG, et al. Advances with glucocorticoids in the treatment of asthma: state of the art. Expert Opin Pharmacother. 2020;21(18):2305–2316.
   PubMed Web of Science ®Google Scholar
• Kerstjens HAM, Disse B, Schröder-Babo W, et al. Tiotropium improves lung function in patients with severe uncontrolled asthma: a randomized controlled trial. J Allergy Clin Immunol. 2011;128(2):308–314.
   PubMed Web of Science ®Google Scholar
• Kerstjens HAM, Engel M, Dahl R, et al. Tiotropium in asthma poorly controlled with standard combination therapy. N Engl J Med. 2012;367(13):1198–1207.
   PubMed Web of Science ®Google Scholar
• Timmer W, Moroni-Zentgraf P, Cornelissen P, et al. Once-daily tiotropium Respimat(®) 5 μg is an efficacious 24-h bronchodilator in adults with symptomatic asthma. Respir Med. 2015;109(3):329–338.
   PubMed Web of Science ®Google Scholar
• Beeh K-M, Kirsten A-M, Dusser D, et al. Pharmacodynamics and pharmacokinetics following once-daily and twice-daily dosing of tiotropium respimat® in asthma using standardized sample-contamination avoidance. J Aerosol Med Pulm Drug Deliv. 2016;29(5):406–415.
   PubMed Web of Science ®Google Scholar
• Lin J, Wan H, Kang J, et al. Add-on tiotropium in Chinese patients with moderate asthma: a pooled subgroup analysis of mezzotina-asthma 1 and 2. Allergy Asthma Immunol Res. 2019;11(4):519–528.
   PubMed Web of Science ®Google Scholar
• Beeh K-M, Moroni-Zentgraf P, Ablinger O, et al. Tiotropium Respimat® in asthma: a double-blind, randomised, dose-ranging study in adult patients with moderate asthma. Respir Res. 2014;15(1):61.
   PubMedGoogle Scholar
• Casale TB, Bateman ED, Vandewalker M, et al. Tiotropium respimat add-on is efficacious in symptomatic asthma, independent of T2 phenotype. J Allergy Clin Immunol Pract. 2018;6(3):923–935.e9.
   PubMed Web of Science ®Google Scholar
• Peters SP, Bleecker ER, Kunselman SJ, et al. Predictors of response to tiotropium versus salmeterol in asthmatic adults. J Allergy Clin Immunol. 2013;132(5):1068–1074.e1.
   PubMed Web of Science ®Google Scholar
• Ohta K, Ichinose M, Tohda Y, et al. Long-term once-daily tiotropium respimat® is well tolerated and maintains efficacy over 52 weeks in patients with symptomatic asthma in japan: a randomised, placebo-controlled study. PLoS One. 2015;10(4):e0124109.
   PubMed Web of Science ®Google Scholar
• Dahl R, Engel M, Dusser D, et al. Safety and tolerability of once-daily tiotropium Respimat ® as add-on to at least inhaled corticosteroids in adult patients with symptomatic asthma: a pooled safety analysis. Respir Med. 2016;118:102–111.
   PubMed Web of Science ®Google Scholar
• Graham LM, Kerstjens HAM, Vogelberg C, et al. Safety of tiotropium Respimat® in black or African-American patients with symptomatic asthma. Respir Med. 2019;155:58–60.
   PubMed Web of Science ®Google Scholar
• Enerzair Breezhaler [Internet]. [cited 2021 Feb 20]. Available from: https://www.ema.europa.eu/en/medicines/human/EPAR/enerzair-breezhaler.
   Google Scholar
• Kerstjens HAM, Maspero J, Chapman KR, et al., Once-daily, single-inhaler mometasone-indacaterol-glycopyrronium versus mometasone-indacaterol or twice-daily fluticasone-salmeterol in patients with inadequately controlled asthma (IRIDIUM): a randomised, double-blind, controlled phase 3 study. Lancet Respir Med. 8(10): 1000–1012. 2020.
   PubMed Web of Science ®Google Scholar
• Gessner C, Kornmann O, Maspero J, et al. Fixed-dose combination of indacaterol/glycopyrronium/mometasone furoate once-daily versus salmeterol/fluticasone twice-daily plus tiotropium once-daily in patients with uncontrolled asthma: a randomised, Phase IIIb, non-inferiority study (ARGON). Respir Med. 2020;170:106021.
   PubMed Web of Science ®Google Scholar
• Trimbow [Internet]. [cited 2021 Feb 20]. Available from: https://www.ema.europa.eu/en/medicines/human/summaries-opinion/trimbow-0.
   Google Scholar
• Virchow JC, Kuna P, Paggiaro P, et al. Single inhaler extrafine triple therapy in uncontrolled asthma (TRIMARAN and TRIGGER): two double-blind, parallel-group, randomised, controlled phase 3 trials. Lancet. 2019;394(10210):1737–1749.
   PubMed Web of Science ®Google Scholar
• Singh D, Virchow JC, Canonica GW, et al. Determinants of response to inhaled extrafine triple therapy in asthma: analyses of TRIMARAN and TRIGGER. Respir Res. 2020;21(1):285.
   PubMed Web of Science ®Google Scholar
• Lee LA, Bailes Z, Barnes N, et al., Efficacy and safety of once-daily single-inhaler triple therapy (FF/UMEC/VI) versus FF/VI in patients with inadequately controlled asthma (CAPTAIN): a double-blind, randomised, phase 3A trial. Lancet Respir Med. 9(1): 69–84. 2021.
   PubMed Web of Science ®Google Scholar
• Polosa R, Russo C, Caponnetto P, et al. Greater severity of new onset asthma in allergic subjects who smoke: a 10-year longitudinal study. Respir Res. 2011;12(1):16.
   PubMedGoogle Scholar
• Lazarus SC, Chinchilli VM, Rollings NJ, et al. Smoking affects response to inhaled corticosteroids or leukotriene receptor antagonists in asthma. Am J Respir Crit Care Med. 2007;175(8):783–790.
   PubMed Web of Science ®Google Scholar
• Yoshida M, Kaneko Y, Ishimatsu A, et al. Effects of tiotropium on lung function in current smokers and never smokers with bronchial asthma. Pulm Pharmacol Ther. 2017;42:7–12.
   PubMed Web of Science ®Google Scholar
• Braman SS, Kaemmerlen JT, Davis SM. Asthma in the elderly. A comparison between patients with recently acquired and long-standing disease. Am Rev Respir Dis. 1991;143:336–340.
   PubMed Web of Science ®Google Scholar
• Sharma G, Goodwin J. Effect of aging on respiratory system physiology and immunology. Clin Interv Aging. 2006;1(3):253–260.
   PubMed Web of Science ®Google Scholar
• Hara J, Kasahara K, Ohkura N, et al. A single institution retrospective study of the clinical efficacy of tiotropium respimat in never-smoking elderly asthmatics with irreversible airflow limitation. Drug Res (Stuttg). 2019;69(4):211–217.
   PubMed Web of Science ®Google Scholar
• Boulet L-P, Franssen E. Influence of obesity on response to fluticasone with or without salmeterol in moderate asthma. Respir Med. 2007;101(11):2240–2247.
   PubMed Web of Science ®Google Scholar
• Mohamed EI, Maiolo C, Iacopino L, et al. The impact of body-weight components on forced spirometry in healthy italians. Lung. 2002;180(3):149–159.
   PubMed Web of Science ®Google Scholar
• Khurana S, Paggiaro P, Buhl R, et al. Tiotropium reduces airflow obstruction in asthma patients, independent of body mass index. J Allergy Clin Immunol Pract. 2019;7(7):2425–2428.e7.
   PubMed Web of Science ®Google Scholar
• FitzGerald JM, Buhl R, Casale TB, et al. Tiotropium add-on therapy reduces seasonal peaks of asthma worsening in adults with symptomatic severe asthma. Eur Respir J. 2020;55(1):190096455
   Web of Science ®Google Scholar
• DuBuske L, Newbold P, Wu Y, et al. Seasonal variability of exacerbations of severe, uncontrolled eosinophilic asthma and clinical benefits of benralizumab. Allergy Asthma Proc. 2018;39(5):345–349.
   PubMed Web of Science ®Google Scholar
• Sears MR. Epidemiology of asthma exacerbations. J Allergy Clin Immunol. 2008;122(4):662–668.
   PubMed Web of Science ®Google Scholar
• Kazani S, Israel E. Long-acting beta-agonists and inhaled corticosteroids: is the whole greater than the sum of its parts? J Allergy Clin Immunol. 2010;125:357–358.
   PubMed Web of Science ®Google Scholar
• Beasley R, Martinez FD, Hackshaw A, et al. Safety of long-acting beta-agonists: urgent need to clear the air remains. Eur Respir J. 2009;33(1):3–5.
   PubMed Web of Science ®Google Scholar
• Bateman ED, Kornmann O, Schmidt P, et al. Tiotropium is noninferior to salmeterol in maintaining improved lung function in B16-Arg/Arg patients with asthma. J Allergy Clin Immunol. 2011;128(2):315–322.
   PubMed Web of Science ®Google Scholar
• Sunther M, Marchon K, Gupta A. Tiotropium in the management of paediatric and adolescent asthma: systematic review. Paediatr Respir Rev. 2020;38:58–62.
   PubMed Web of Science ®Google Scholar
• Raissy HH, Kelly HW. Tiotropium bromide in children and adolescents with asthma. Paediatr Drugs. 2017;19(6):533–538.
   PubMed Web of Science ®Google Scholar
• Vogelberg C, Engel M, Moroni-Zentgraf P, et al. Tiotropium in asthmatic adolescents symptomatic despite inhaled corticosteroids: a randomised dose-ranging study. Respir Med. 2014;108(9):1268–1276.
   PubMed Web of Science ®Google Scholar
• Hamelmann E, Bateman ED, Vogelberg C, et al. Tiotropium add-on therapy in adolescents with moderate asthma: a 1-year randomized controlled trial. J Allergy Clin Immunol. 2016;138(2):441–450.e8.
   PubMed Web of Science ®Google Scholar
• Hamelmann E, Bernstein JA, Vandewalker M, et al. A randomised controlled trial of tiotropium in adolescents with severe symptomatic asthma. Eur Respir J. 2017;49(1):49.
   Web of Science ®Google Scholar
• Vogelberg C, Moroni-Zentgraf P, Leonaviciute-Klimantaviciene M, et al. A randomised dose-ranging study of tiotropium Respimat® in children with symptomatic asthma despite inhaled corticosteroids. Respir Res. 2015;16(1):20.
   PubMedGoogle Scholar
• Szefler SJ, Murphy K, Harper T, et al. A phase III randomized controlled trial of tiotropium add-on therapy in children with severe symptomatic asthma. J Allergy Clin Immunol. 2017;140(5):1277–1287.
   PubMed Web of Science ®Google Scholar
• Vrijlandt EJLE, El Azzi G, Vandewalker M, et al. Safety and efficacy of tiotropium in children aged 1-5 years with persistent asthmatic symptoms: a randomised, double-blind, placebo-controlled trial. Lancet Respir Med. 2018;6(2):127–137.
   PubMed Web of Science ®Google Scholar
• National Guideline Centre. Chronic asthma management. [cited 2021 Feb 20]. Available from: https://www.nice.org.uk/guidance/ng80/evidence/full-guideline-chronic-asthma-management-pdf-4656179345
   Google Scholar
• Kang JY, Rhee CK, Kim JS, et al. Effect of tiotropium bromide on airway remodeling in a chronic asthma model. Ann Allergy Asthma Immunol. 2012;109(1):29–35.
   PubMed Web of Science ®Google Scholar
• O’Connor BJ, Towse LJ, Barnes PJ. Prolonged effect of tiotropium bromide on methacholine-induced bronchoconstriction in asthma. Am J Respir Crit Care Med. 1996;154(4):876–880.
   PubMed Web of Science ®Google Scholar
• Liccardi G, Salzillo A, Calzetta L, et al. Can an increased cholinergic tone constitute a predictor of positive response to tiotropium in patients with moderate asthma? J Allergy Clin Immunol Pract. 2016;4(4):791–793.
   PubMed Web of Science ®Google Scholar
• Zannin E, Pellegrino R, Di Toro A, et al. Parasympathetic stimuli on bronchial and cardiovascular systems in humans. PLoS One. 2015;10(6):e0127697.
   PubMed Web of Science ®Google Scholar